2 Drug Stocks Moving in Opposite Directions Today

The FDA handed out decisions to ZGNX and PHAS

Managing Editor
Apr 9, 2019 at 9:57 AM
facebook X logo linkedin


Near the bottom of the Nasdaq this morning is Zogenix, Inc. (NASDAQ:ZGNX), down 24.8% to trade at $38.97, after the Food and Drug Administration (FDA) refused to review the drugmaker's marketing application for its seizure medicine. Guggenheim responded by downgrading the stock to "neutral" from "buy" while slashing its price target to $40 from $70. Three other brokerage firms issued price-target cuts as well, including to $58 from $71 at Mizuho, which called the FDA decision "unexpected." 

This is shaping up to be Zogenix stock's worst day in years. The drop breaks ZGNX out of its channel of higher highs and lows that started from its Christmas Eve bottom near $33. And more bear notes could pressure the shares even lower, since all eight of the brokerages in coverage of the security rated it a "strong buy" coming into today, while its consensus 12-month price target of $61.90 is now a more than 60% premium to its current perch.

On the other end of the spectrum is PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS), up 23.2% to trade at $15.48, and one of the best stocks on the Nasdaq this morning. Powering the surge today is the FDA granting "breakthrough therapy" status to the company's experimental antiplatelet activity drug PB2452. In response, Stifel hiked its price target to $18 from $14, uncharted territory for the stock, with the October initial public offering (IPO) sitting all the way down at $5. 

In 2019 alone, PhaseBio stock has now more than quadrupled thanks to a round of encouraging data from PB2452. Analysts are already sold on the red-hot biotech name. All four in coverage rate it a "buy" or better, and the average 12-month price target sits right at $18. 
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI